KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Cash from Financing Activities (2020 - 2025)

Recursion Pharmaceuticals' Cash from Financing Activities history spans 6 years, with the latest figure at $132.0 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 1140.77% year-over-year to $132.0 million; the TTM value through Dec 2025 reached $521.5 million, up 71.49%, while the annual FY2025 figure was $521.5 million, 71.49% up from the prior year.
  • Cash from Financing Activities reached $132.0 million in Q4 2025 per RXRX's latest filing, down from $251.3 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $463.7 million in Q2 2021 to a low of -$11.1 million in Q3 2021.
  • Average Cash from Financing Activities over 5 years is $78.9 million, with a median of $15.2 million recorded in 2024.
  • The largest YoY upside for Cash from Financing Activities was 121288.74% in 2021 against a maximum downside of 104.83% in 2021.
  • A 5-year view of Cash from Financing Activities shows it stood at $3.8 million in 2021, then skyrocketed by 3779.24% to $147.3 million in 2022, then crashed by 45.23% to $80.7 million in 2023, then crashed by 86.81% to $10.6 million in 2024, then surged by 1140.77% to $132.0 million in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Cash from Financing Activities are $132.0 million (Q4 2025), $251.3 million (Q3 2025), and $97.7 million (Q2 2025).